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Objective: To analyze the impact of age at implantation on
the cost-effectiveness of cochlear implantation (CI).
Study Design: Cost-utility analysis in an adapted Markov
model.
Setting: Adults with profound postlingual hearing loss in a
‘‘high income’’ country.
Intervention: Unilateral and sequential CI were compared
with hearing aids (HA).
Main Outcome Measure: Incremental cost-effectiveness
ratio (ICER), calculated as costs per quality adjusted life
year (QALY) gained (in CHF/QALY), for individual age and
sex combinations in relation to two different willingness to
pay thresholds. 1 CHF (Swiss franc) is equivalent to 1.01
USD.
Results: When a threshold of 50,000 CHF per QALY is
applied, unilateral CI in comparison to HA is cost-effective
up to an age of 91 for women and 89 for men. Sequential CI
in comparison to HA is cost-effective up to an age of 87 for
women and 85 for men. If a more contemporary threshold
of 100,000 CHF per QALY is applied, sequential CI in
comparison to unilateral CI is cost-effective up to an age of
80 for women and 78 for men.
Conclusions: Performing both sequential and unilateral CI is
cost-effective up to very advanced ages when compared
with hearing aids. Key Words: Adults—Age—Cochlear
implant—Cost—Cost-effect iveness—Cost-ut i l i ty—
Discount—Effectiveness—Implantation—Markov—Quality
adjusted life year—Quality—Related—Sensitivity—Utility.
Otol Neurotol 40:xxx–xxx, 2019.
The worldwide number of patients who underwent
cochlear implantation (CI) has increased constantly over
the past decades. Reports have indicated that 25,000
patients had cochlear implants by 1998 (1) and this
increased to 324,200 by 2012 (2). According to cochlear
implant manufacturers, the number of implanted patients
may have reached 500,000 in 2017 and is likely to
continue to grow rapidly. According to the World Health
Organization (WHO, www.who.int), approximately 11.7
million people worldwide suffer from profound hearing
loss. Sequential CI and implantation in the elderly is
becoming routine practice in many countries. In addition,
implantation for unilateral deafness or tinnitus is already
standard in several countries (e.g., Germany) and is likely
to increase the indication for implantation worldwide
(3,4). The total cost of a CI includes the preoperative
evaluation, the implanted device itself, the surgery with
the attendant hospitalization, and the postoperative reha-
bilitation. The first CI with a commercialized multi-
electrode device was performed 40 years ago (5), but
the continuous technical improvements and the need for
comprehensive pre- and postoperative care have gener-
ally kept the costs high. Since the recovery of lost hearing
is associated with an immense gain in the quality of
life (QoL), CI has been shown to be cost-effective for
many different situations in both pediatric and adult
populations (6,7).
Nevertheless, limited economic resources, longevity,
and recently developed expensive therapeutic options in
various medical fields have caused a rise in health related
cost-effectiveness discussions. The quality adjusted life
year (QALY) quantifies the benefits of an intervention as
a function of QoL and time duration. The incremental
cost-effectiveness ratio (ICER) describes the difference
in costs of two different interventions in relation to the
achieved benefit by the better intervention (in costs per
QALY gained). Therefore, it allows a comparison of two
different interventions considering both costs and gain in
QoL. Costs are measured in monetary units, the gain is
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measured in QALY. For example, if a more expensive
therapy brings a gain of 0.5 QALY, but costs 10,000 USD
more, then the ICER of this more expensive therapy in
comparison to the less expensive therapy would be
20,000 USD/QALY. The exact formula is presented in
the methods section. There is an ongoing debate on what
is a reasonable allowable cost of a gained QALY.
The commonly applied ICER threshold is $50,000, but
recently a shift to higher numbers ($100,000, $150,000,
$200,000, and $300,000) are discussed and often recom-
mended (8).
From a medical point of view, CI in the elderly is
highly effective (9). However, as the QALY is directly
influenced by the duration of the achieved benefit, the
calculated cost-effectiveness depends on the remaining
life expectancy. While for unilateral CI such calculations
might seem ethically questionable, the evaluation of the
cost-effectiveness of bilateral CI in the elderly population
in the context of increasing medical costs and limited
economic resources seems reasonable.
At first glance, cost-effectiveness considerations are
primarily political, economic, and ethical questions.
Nonetheless, from a physician’s view, they allow stan-
dardized comparisons of different therapies and proce-
dures, across from different specialties.
The goal of this cost-utility analysis was to analyze the
cost structures and the cost-effectiveness of CI in a ‘‘high
income country,’’ as defined by the WHO, with a focus
on age and sex for both unilateral (UNI) and sequential
(SEQ) CI.
PATIENTS AND METHODS
As in previous studies on cost-effectiveness of CI (7),
reporting of methods and results are guided by the Consolidated
Health Economic Evaluation Reporting Standards (10).
Setting
The target population were adults with severe to profound
postlingual hearing loss. Qualification criteria for CI are
listed in the national guidelines for CI and follow-up care
(11). These guidelines require that spoken language cannot
be sufficiently understood with a fitted hearing aid (HA) and
that the patient exhibit anatomical conditions that allow for
implantation.
Cost parameters were collected for the year 2017 in a public
tertiary referral hospital setting in Switzerland. The country
population in 2016 is estimated 8.4 million. Life expectancy is
81 years for men and 85 years for women. In 2016, 234 CI were
performed in five national centers (four of them university
hospitals). Since the first implantations in 1977, by 2016 a total
of 3,096 patients were implanted (12).
Patient Cohort for Comparison
For a better comparison of published data in literature, an
own patient cohort in the Swiss setting was analyzed retrospec-
tively for their mean age, device failure rate, and non-user rate.
Included were 100 adult patients, who received their first
implant and were implanted consecutively between 2010 and
2013, allowing for a follow-up rate of 5 years.
Costs
Detailed costs, timing, number of visits, and the type of the
different examinations are listed in Table 1. Mandatory health
insurance and social security covers most of the costs. A small
co-pay is paid by the patient. Prices are set on a national level by
the Swiss health care system. The hospitalization and operation
costs are reimbursed by the insurance on a flat rate base. This
flat rate includes the hospitalization, the implantation, the
implant, and the overhead costs. The number and types of
visits are standardized at the authors’ institution. Table 2 shows
the recurring costs of HA and cochlear implant, as well as the
corresponding device replacement intervals (‘‘time frame’’).
For illustration, the ‘‘yearly average’’ costs are shown as well.
For the evaluation of the model, the original values with the
associated intervals were used (10 years for CI and 6 years for
HA). For the HA, a reimbursement rate of 6,140 CHF was used
for the calculations. Formally, this is the amount for HA, which
was available to all hearing impaired patients every 6 years until
2011 in our system. Since then, the general amount has declined
to 1,650 CHF every 6 years. Patients with a severe to profound
bilateral hearing loss, as in our study population, qualify for a
‘‘hardship case,’’ which warrants full coverage. On average this
corresponds to the amount of 6,140 CHF every 6 years.
The HA situation reflects the bilateral HA status. As we
analyze the situation for patients with bilateral severe to pro-
found hearing loss, it is assumed that the costs for HA no longer
apply once a CI is successfully implanted. If a patient benefits
from a HA on the contralateral side after UNI, the implantation
of the second side would be offered. As HA are reimbursed
every 6 years, it is assumed that the patients would use the HA
they already possess in the meantime. However, a generous use
of HA, even with little benefit, is advocated. Some patients will
continue to use a HA after UNI continuously and the effect of
the additional HA costs for this situation is analyzed in a
separate sensitivity analysis.
In case of device failure and reimplantation, a different flat
rate value of 15,866 CHF is used. This represents the costs
billed by the hospital, with the new implant covered by the
manufacturer. Details on the time frames and failure rates are
mentioned in the next section.
Only direct costs like preoperative evaluation, MRI, audiol-
ogy tests, hospitalization, rehabilitation, and device replace-
ment costs were used for calculations. Current discount rates
published by the Swiss National Bank are 0%. To allow
comparison of the results with other studies and places, the
calculations were repeated using various discount rates (0, 1, 3,
and 5%). At the time of writing, the currency exchange rate of
CHF to USD was 1 CHF to 1.01 USD.
Probabilities, Health Utilities, and Replacement Costs
Reported device failure rates vary and have been reported
ranging from 1.84% (13) to 3.4% (14), 4.8% (15), and 5.1%
(16). In case of device failure, Bhatt et al. (16) describe a mean
duration from implantation to device failure of 1.9 years with a
range from 0.04 to 6 years. In the basic model, it is assumed, that
the manufacturer would provide the new device (10-year
manufacturer warranty in our system). In the sensitivity analysis
section (Results), we relax this assumption. In our own patient
cohort, we found a device failure rate of 2%. For the calcu-
lations, a value of 3.4% was used (the mean of the five
mentioned values).
Summerfield and Marshall (17) report a non-user rate of 2%
after 6 months with a plateau of 6% after 4 to 7 years. In our
cohort, 4% were non-users after 5 years, comparable to the
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4.7% reported by Bhatt et al. (16). Other studies reported
1.1% (18) and 2.78% (19).
For calculations, we used a mean probability rate of 3.7% for
non-users. For our analysis, the device failure and non-user
probabilities were applied both after 2 years and 1 year, respec-
tively. This was in accordance with our clinical observations,
where device failure and non-users are identified to be within
these intervals. Additionally, a sensitivity analysis for different
device failure and non-users rates was performed.
In a large review, Crowson et al. (6) evaluated health utility
values and calculated weighted-average QoL gains for both
generic and diseases specific QoL measures from published
data up to 2017. Their weighted averages for disease specific
measures were used in our calculations and are listed in Table 3.
In summary, these health utilities values represent the change
in the QoL achieved by the intervention and are based on
questionnaire results (e.g., Health Utility Index-Mark 3 (20),
Nijmegen Cochlear Implant Questionnaire NCIQ (21), and
others).
Analysis
Adults with bilateral HA, unilateral CI, and bilateral CI were
compared in an adapted Markov model (22). A Markov model
is typically used to predict the future behavior of a complex
system (sometimes illustrated with a decision tree), based on
actual known probabilities. A mathematically strict Markov
model assumes that the probabilities applied are the same for
each step (year). In our model, age related mortality and the
interventions create different probabilities. Also, instead of
using averaged yearly costs, the model took into account the
real costs and time intervals (e.g., HA replacement costs of
6,140 CHF every 6 yrs).
Figure 1 shows the decision tree with decision nodes
(squares) and event nodes (circles). The probabilities mentioned
above are applied at each of the event nodes. Bilateral CI option
actually represents the sequential implantation. In the author’s
institution, simultaneous bilateral implantation is routine prac-
tice in pediatric cases only. Eventually, all of the patients end up
in one of the following final states: HA, UNI, SEQ.
TABLE 1. One time costs
Time Point (in days) HA UNI SEQ
1. HA costs
HA initial costs – 6,140 - -
2. First CI costs
Initial specialist consultation 0 – 338 –
Audiology assessment 0 – 398 –
Subsequent specialist consultation 7 – 275 –
MRI 83 – 710 –
Subsequent specialist consultation (surgeon) 97 – 98 –
Implantation (hospitalization, implantation, implant, overhead costs) 157 – 30,866 –
General practitioner consultation (removal of stitches) 164 – 44 –
1st fitting of sound processor 185 – 517 –
Sound processor 185 – 12,349 –
2nd fitting of sound processor 192 – 391 –
3rd fitting of sound processor 213 – 391 –
Audiology assessment 1 241 – 729 –
Audiology assessment 2 325 – 729 –
Audiology assessment 3 409 – 729 –
Weekly training with speech therapist Up to 365 – 2,520 –
3. Second CI costs
Initial specialist consultation 0 – – 338
Audiology assessment 0 – – 398
Subsequent specialist consultation 7 – – 275
Subsequent specialist consultation (surgeon) 97 – – 98
Implantation (hospitalization, implantation, implant, overhead costs) 157 – – 30,866
General practitioner consultation (removal of stitches) 164 – – 44
1st fitting of sound processor 185 – – 517
Sound processor 185 – – 12,349
2nd fitting of sound processor 192 – – 391
3rd fitting of sound processor 213 – – 391
Audiology assessment 1 241 – – 729
Audiology assessment 2 325 – – 729
Audiology assessment 3 409 – – 729
Weekly training with speech therapist Up to 365 – – 2,520
Total incremental costs UNI versus HA – 51,084 –
SEQ versus UNI – – 50,374
HA indicates hearing aids; SEQ, sequential cochlear implantation; time point (in days), gives an idea on the time course of CI with the
average intervals between the different examinations; UNI, unilateral cochlear implantation.
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The yearly all-cause mortality, with slight differences for
men and women, was extracted from Swiss life tables from the
Swiss Federal Statistical Office (23). The time unit used for
analysis was 1 year. Since the utility scores that were used were
collected from adult populations, the analyses start at age 18.
To compare different interventions, four values were calcu-
lated in a first step: the cost of intervention 1 (C1), the cost
intervention 2 (C2), the health utility value of intervention 1
(H1), and the health utility value of intervention 2 (H2). The
costs are in CHF, the health values in QALY. The ICER was
then calculated according to the formula ICER¼ (C2 – C1)/
(H2 – H1), resulting in a value that represents the incremental
cost per QALY (in CHF/QALY). The ICER was calculated for
each combination of age (18–110 yrs) and sex. The time
horizons are age and sex dependent and represent the individu-
als remaining life expectancy. All the costs and health utility
values were calculated over the expected patient’s lifetime.
In summary, the incurring costs for each decision (of the
decision tree) were applied in a year-by-year calculation, with
continuously adapting the age dependent mortality rate.
As the resulting ICERs are age dependent, they were plotted
as curves (Fig. 2). To further characterize these curves, a ‘‘trend
point’’ was calculated. This point describes the age, at which
the steepness of the curve increases by 1,000 CHF per year.
RESULTS
General Costs
HA start with one-time costs of 6,140 CHF which is
incurred again after each 6-year period. In addition,
batteries and specialist consultations, add an average
yearly costs of 1,253 CHF. The cost for unilateral CI
was found to be 51,084 CHF and a second, sequential
bilateral CI, was 50,749 CHF. In addition, the average
yearly costs were 2,208 and 3,843 CHF, respectively
(Tables 1 and 2).
Incremental Costs and Outcomes
Figure 2 shows the ICER as a function of age at
intervention. The younger a patient is at implantation,
the longer he or she will enjoy an improved QoL. This
makes the intervention more cost-effective. The
highlighted horizontal 50,000 and 100,000 CHF lines
represent a conservative (50,000) and a more contempo-
rary (100,000) cost-effectiveness threshold. Precise costs
per QALY gained for different ages are shown in Table 3
(right half). For example, when a 20-year-old woman
upgrades from HA to UNI, her ICER (the cost of the
gained benefit) is 6,261 CHF per QALY. When an 80-
year-old woman upgrades from HA to UNI, her ICER is
22,124 CHF, as her remaining life expectancy is shorter.
Table 4 shows three characteristic ages: 1) the age at
which the 50,000 CHF threshold is crossed, 2) the age at
which the 100,000 CHF threshold is crossed, and 3) the
‘‘trend point,’’ (as defined above) which is illustrated in
Figure 2. With a threshold of 50,000 CHF, performing
unilateral CI in comparison to HA is cost-effective up to
an age of 91 for women and 89 for men. Sequential CI in
comparison to HA is cost-effective up to an age of 87 for
women and 85 for men. Sequential CI in comparison to
unilateral CI is cost-effective up to an age of 80 for
women and 78 for men, when the more contemporary
threshold of 100,000 CHF per QALY is applied.




























UNI versus HA 51,084 955 0.28 6,261 6,459 7,499 7,891 10,425 11,461 22,124 25,745
SEQ versus HA 101,459 2,590 0.38 10,818 11,111 12,652 13,234 17,020 18,528 33,974 38,233
SEQ versus UNI 50,374 1,635 0.1 25,101 25,730 29,345 30,710 40,371 44,323 97,810 114,408
Shown are incremental costs and incremental health values in the first three rows. The right eight rows show different age and sex
combinations and the incremental costs for 1 QALY gained (in CHF/QALY) for the different situations. HA indicates hearing aids; SEQ,
sequential cochlear implantation; UNI, unilateral cochlear implantation.
TABLE 2. Recurring costs
Time Frame HA UNI SEQ
1. HA
Batteries Yearly 60 – –
Replacement costs Every 6 years 6,140 – –
Specialist consultation Every 2 years 339 – –
2. CI
Batteries Yearly – 400 800
Sound processor Every 10 years – 12,349 24,698
Follow–up fitting Yearly – 391 391
Audiology follow-up assessment Every 2 years – 365 365
Yearly average 1,253 2,208 3,843
HA indicates hearing aids; SEQ, sequential cochlear implantation; UNI, unilateral cochlear implantation.
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Table 4 shows also the effect that applying a discount
rate of 1, 3, or 5% has on the age at which a threshold line
is crossed. The ICER of unilateral CI in comparison to
hearing aids is 6,261 CHF for a 20-year-old woman,
7,499 CHF for a 40-year-old woman, 10,425 CHF for a
60-year-old woman, and 22,124 CHF for an 80-year-
old woman.
Sensitivity Analysis
Some of the uncertainties inherent in such a model are
addressed by a sensitivity analysis. Parameter changes
were made in the discount factor (shown above, Table 4),
non-user rate, device failure rate, and device failure
coverage.
When the lowest device failure rates and non-user rates
found in literature were applied (1.84 and 1.1%, respec-
tively), the age at which the 50,000 CHF threshold is
crossed, changes by a maximum of 1 year as compared
with the original calculation. For example, in the UNI
versus HA situation in women, the point where the curve
crosses the 50,000 CHF threshold line moved from
91 years to 92. When the highest rates reported in
literature were used (5.1 and 6%, respectively), the
maximum change was also 1 year (SEQ versus HA in
men, change from 85 to 84 yrs). These effects seem to
be marginal.
As discussed further above, the cost of reimplantation
was 15,866 CHF under the assumption that the device
FIG. 2. ICER curves. Y-axis shows the ICER (the cost of one QALY gained) in dependence of age at intervention (x-axis) for women (A)
and men (B). The highlighted horizontal lines show the cost-effectiveness thresholds (the conservative threshold at 50,000 CHF and the
more contemporary thershold at 100,000 CHF). In the UNI versus HA curve, the ‘‘trend point’’ is shown for illustration. HA indicates hearing
aids; ICER, incremental cost-effectiveness ratio; QALY, quality adjusted life year; UNI, unilateral.
FIG. 1. Decision tree. Squares represent decisions. Circles represent events. The probabilities are applied at the forks of the event nodes.
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was covered by manufacturer warranty or that the patient
did not require a new implant (electrode displacement
etc.). In some revisions however, the CI needs to be
replaced and is not covered by the manufacturer’s war-
ranty, resulting in costs of 30,866 CHF. To address this
uncertainty, different device failure coverage averages
were used for the calculation, but showed only a marginal
effect. The only noticeable change was observed in the
SEQ versus UNI situation in men, when a 0% manufac-
turer coverage was applied. The age, at which the 50,000
CHF threshold is crossed, moved from 64 to 63 years.
If a unilaterally implanted patient continues to use a
HA on the contralateral side (additional costs of 3,000
CHF every 6 yrs), the cost-effectiveness slightly changes,
for both, the UNI versus HA situation and the SEQ versus
UNI situation. The age at 50,000/QALY (Table 4)
changes as follows: UNI versus HA from 91/89 (f/m)
to 89/86; SEQ versus UNI from 67/64 (f/m) to 70/66.
DISCUSSION
In contrast to other studies on cost-effectiveness for CI
or other medical interventions in general, our model
specifically targets the effect of the age at the time of
intervention. The ICERs are therefore different for each
individual age. All the other studies looked at the target
population as a whole.
To compare our results with the results of the other
studies, we calculated the average age of our own CI
patient cohort (51 yrs). In our model, the ICER for the
UNI versus HA situation is 8,746 CHF for a 51-year-old
woman and 9,393 CHF for a 51-year-old man. This
compares to an ICER of 9,799 AUD (equivalent to
7,313 CHF) found by Foteff et al. (7) in an Australian
setting and Chen et al. (24), who found an ICER of 9,426
$CAN (equivalent to 6,993 CHF) in a Canadian popula-
tion. In another study in the UK (25), an ICER of 14,163
pounds (equivalent to 18,884 CHF) was found. Overall,
these numbers from 2014 to 2017 from different coun-
tries and systems are similar, while the UK (2009) is
an outlier.
To compare our results in the SEQ versus HA situa-
tion, an ICER of 14,506 CHF for a 51-year-old woman
and 15,463 CHF for a 51-year-old man were calculated in
our population. These numbers can be compared with the
14,658 $CAN (equivalent to 10,882 CHF) published by
Chen et al. (24).
For the SEQ versus UNI situation, our ICER was
33,854 CHF for a 51-year-old woman and 36,219
CHF for a 51-year-old man. In the Canadian population
it was 55,020 $CAN (equivalent to 40,846 CHF) and
26,765 AUD (equivalent to 19,870 CHF) in the Austra-
lian population. One reason for this variance is that the
Australian value describes simultaneous CI in compari-
son to HA. Apart from that, health utility values for the
SEQ versus UNI situation are difficult to measure and
vary in literature.
The health utility measures for the UNI versus HA
situation are better studied and similar values are used in
different publications. Differences in costs between our
population and the costs of other countries in the UNI
versus HA situation may reflect the cost structures in the
different countries. The gross domestic product at pur-
chasing power parity per capita (GDP PPP PC), defined
by the International Monetary Fund (www.imf.org),
describes the gross domestic product in relation to the
population number and the standardized ‘‘international
dollar.’’ The GDP PPP PC is 61,360, 48,141, 49,882, and
43,620$ for Switzerland, Canada, Australia, and the UK
respectively (the USA as comparison is 59,495$). Popu-
lation characteristics of Switzerland, Canada, Australia,
and the UK are also comparable. Life expectancy, the
main parameter on which our model is based, is practi-
cally the same. For men/women it is 81/85, 81/85, 81/85,
and 80/83 years respectively (in the USA 76/81 yrs)
(www.who.int). The population sizes are different (8.4
mil, 36.7 mil, 24.6 mil, and 66.0 mil, respectively; 325.7
mil in the USA as a comparison), but does not affect
our model.
Figure 2 shows the most relevant information as it
summarizes graphically the ICER values for each age
and sex combination in relation to different interven-
tions and thresholds: compared with HA, performing a
UNI or SEQ is cost-effective up to very advanced ages
for both threshold values (50,000 CHF and 100,000
CHF). When a 100,000 CHF threshold is used, the
analysis indicates that SEQ compared with UNI is also
cost-effective up to an age of 80 years for women and
TABLE 4. Specific results
Treatment Group Comparison Gender Age at 50,000/QALY Age at 100,000/QALY Age at ‘‘trend point’’
UNI Versus HA F 91 (92/92/93) 103 (103/104/104) 78
M 89 (90/91/91) 102 (103/103/103) 76
SEQ Versus HA F 87 (88/89/90) 102 (102/103/103) 74
M 85 (86/87/89) 101 (101/102/103) 72
Versus UNI F 67 (69/72/74) 80 (81/82/83) 62
M 64 (66/69/71) 78 (78/80/81) 58
Shown are the specific ages when the thresholds are crossed and the age at the ‘‘trend point.’’ The values in parenthesizes show the age if a
discount factor is applied (1, 3, 5%). For example, if a discount rate of 5% is applied in the calculations, the age at which the 50,000 CHF
threshold is crossed for women (UNI versus HA), changes from 91 to 93 years.
HA indicates hearing aids; SEQ, sequential cochlear implantation; UNI, unilateral cochlear implantation.
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78 for men. The shape of the curves can be divided by
what was defined as a ‘‘trend point’’ into a flat and a
steep portion. The flat section depicts the age range in
which the intervention is exceptionally cost-effective.
That is, a unilaterally implanted woman before age 78
would be ‘‘highly cost-effective’’ but the procedure
remains cost-effective until age 91 (and even until age
103 if the 100,000 threshold is used). Our results also
indicate that SEQ is highly cost-effective as compared
with HA regardless of age. The results are less favor-
able when comparing SEQ to UNI. The effect of the
second implant in relation to the first implant is, due to
the immense effect of the first implant, smaller. The
effect of the second implant is harder to measure in
questionnaires and less published data are available
(6). Nevertheless, with contemporary threshold values
(8), our results also allow for SEQ up to highly
advanced ages.
In summary, cost and age are practically no reason to
argue against CI in an otherwise suitable patient.
Limitations of the presented study are the health
utility values, which are taken from literature (6) and
represent values for an average study population. One
might argue, that the health utilities scores change for
each age category and that an elderly population might
have less benefit and therefore the implantation at
high age is less cost-effective. Although we did not
assess health utility values for older populations, the
impact on hearing loss in the elderly, especially in
combination with depression and dementia, is well
known (26). A robust clinical effectiveness of CI in
the elderly was shown by Rohloff et al. (9). We,
therefore, assume that our results with respect to
the elderly are reasonable.
However, more research on utility values for different
groups and indications (e.g., single sided deafness) and
age categories would be of great interest for future studies
on cost-effectiveness of CI.
Generally, the limitations of a mathematical model are
that certain assumptions are required. These assumptions
were made in accordance with our clinical experience.
Additionally, our assumptions were tested with a sensi-
tivity analysis, which showed only very small changes in
the results. Still, there are assumptions that remain
debatable. For example, it is questionable if all patients
use the available 6,140 CHF to replace their HA every 6
years. Some might choose to go for longer intervals, even
though there are no out of pocket costs associated with
the 6-year interval.
Finally, ICERs allow comparisons of the cost-effec-
tiveness of interventions from different medical fields.
Studies have shown ICERs of 88,903$/QALY for total
knee replacement (27) and 5,629$/QALY for laser photo-
coagulation for age-related macular degeneration (28).
Bae and Mullins (29) reviewed 54 articles and found a
mean ICER of $138,582/QALY for cancer-specific
drug interventions.
These values can put the ICER of sequential CI into a
broader context.
CONCLUSION
Sequential and unilateral CI is highly cost-effective
when compared with hearing aids.
When compared with unilateral CI, sequential CI is
cost-effective up to around 80 years when a threshold
value of 100,000 CHF is applied.
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